Melanoma metastasis to the brain is associated with a poor prognosis. We sought to determine patient demographics and primary tumor factors associated with the development of brain metastasis (BM) and survival. We also investigated whether the BM detection setting (routine screening vs. symptomatic presentation) affected clinical outcomes. A database of melanoma patients seen from 1999 to 2015 at our institution was reviewed to identify patients who developed BM. Patients with BM were matched by initial stage with patients who did not develop BM as a control group. Patient demographics, primary tumor characteristics, and clinical outcomes were analyzed. A total of 123 patients with BM were matched by initial presenting stage to 237 patients without BM. The characteristics of the primary melanoma tumor associated with BM development included location on the scalp (P = 0.030), nodular histologic type (P = 0.020), and Breslow depth more than 4 mm (P = 0.048), whereas location on the leg was associated with decreased BM risk (P = 0.006). In patients with BM, time to first recurrence for melanomas of the scalp was significantly shorter (10.8 vs. 24.8 months, P = 0.007) than nonscalp head and neck tumors. Patient stage, tumor depth, nodular type, and ulceration were also associated with worse clinical outcomes. There were no differences in the clinical outcomes between patients whose BM were detected upon routine screening versus those detected upon symptomatic presentation. In summary, factors predictive of development of BM included primary scalp location, nodular type, and depth. In BM patients, scalp location, stage, tumor depth, nodular type, and ulceration, but not detection setting, were associated with worse clinical outcomes. Melanoma Res 27:477-484
Introduction
In the USA, invasive melanoma is the fifth most common type of cancer in men and the seventh most common type of cancer in women, with 76 380 new cases predicted in 2016 and increasing incidence and mortality rates [1] . After lung and breast cancer, melanoma is the most common cancer that metastasizes to the brain [2] . Approximately 10% of patients with a history of invasive melanoma will ultimately develop brain metastasis (BM) [2] , which contributes significantly toward melanoma-analyzing additional patient demographic and primary tumor factors that may be associated with the development of BM, our aim was to investigate the impact of BM detection setting (routine screening vs. symptomatic presentation) on clinical outcomes. We also separately examined clinical outcomes of scalp primary tumors, given their unique histopathology and patterns of recurrence relative to other head and neck primary sites.
Patients and methods

Patients
This project was approved by the University of Utah Institutional Review Board (#76927). Our database architect (C.B.R.) initially queried our prospectively accrued Melanoma Clinical Cancer Database (∼5500 patients, years 1999-2015) for melanoma patients with BM who did not have multiple primary tumors and had a diagnosis of BM recorded on or after the date of the primary tumor. We identified 134 unique patients and then excluded those with primary of ocular melanoma (two patients), gastrointestinal or esophageal melanoma (four patients), preceding diagnosis of other malignancy (except nonmelanoma skin cancer) such as lung, breast, or colon cancer (two patients), history of greater than one primary invasive melanoma (one patient), and those with calvarial metastasis, but without BM (two patients). After these exclusions, a total of 123 patients with BM remained for study. A biostatistician (K.M.B.) randomly selected controls from the same database to obtain approximately double the number of patients without BM in each stage category. Briefly, patients were first stratified by stage and then for each stage stratum, they were permuted randomly using the 'sample' command in R software ( version 3.2.1; R Foundation for Statistical Computing, Vienna, Austria). For each grouping, approximately twice the number of patients with BM were selected to serve as controls, starting at the top of the permuted list of patients. A total of 237 patients were thus identified as not having developed BM and served as the control group.
Data analysis
The accuracy of all data for all patients was confirmed by manual review of the electronic medical record. Variables for which data entries in the database and medical record were missing or not explicitly stated were considered unknown. Mitotic rate and the presence of nevus precursor in the primary melanoma specimen were not analyzed because data were missing or could not be confirmed in the majority of patients with BM. Analyses comparing the patients with BM and the controls without BM were carried out using R software. Fisher's exact test was used for comparisons of categorical data. Multivariate analysis was carried out using a logistic regression model to include all variables that were significant on univariate analysis. Analyses of clinical outcomes in the patients with BM were carried out using GraphPad Prism software (version 6.01; GraphPad Software, Inc., La Jolla, California, USA). Patients presenting with an event such as recurrence or BM at time zero were excluded from analyses of clinical outcomes. Log rank (Mantel-Cox) tests were used to compare survival curves. P value less than 0.05 were considered statistically significant.
Results
Factors associated with the development of brain metastasis
We identified 123 patients with melanoma BM and 237 stage-matched patients without BM. Their demographics are summarized in Table 1 . A comparison of the two cohorts confirms that they are matched for stage (P = 1.00). There was no predilection for male sex (P = 0.12) or a family history of melanoma (P = 0.14). Both groups were divided into approximate quartiles by age and patients with BM were more likely to be in the 40-49 age group of years (P = 0.038).
The primary tumor characteristics of the two groups are summarized in Table 2 . Analysis of primary tumor body site indicated several significant differences. First, patients with BM were significantly more likely to have a tumor that originated on the scalp (P = 0.03) and significantly less likely to have a tumor that originated on an extremity (P = 0.006). On multivariate analysis, extremity location remained negatively associated with the development of BM (P = 0.017). Second, patients with BM were significantly more likely to have a nodular melanoma (NM) histologic type (P = 0.02), although global comparison of all histologic types was not significant (P = 0.11). With respect to Breslow depth, patients with BM were significantly less likely to have primary tumors less than 1 mm (P = 0.046) and significantly more likely to have primary tumors more than 4 mm (P = 0.048), although a global comparison (for trend) of depth quartiles was not significant (P = 0.11).
We found a significant correlation between Breslow depth and NM type (P < 2.2e − 16), and in multivariate analysis, NM type was no longer a significant predictor and tumor depth trended toward significance (P = 0.058).
No differences were observed between the two groups with respect to ulceration of the primary tumor (P = 0.27). Finally, there was no difference in driver mutations detected, although mutation testing was not performed in most patients without BM (Table 2) .
Clinical characteristics of patients with brain metastasis
In patients who ultimately developed BM, the most common first site of melanoma recurrence was the brain (33%), followed by the lung (23%), skin (21%), and lymph node (16%). The most common cutaneous site of recurrence was the head and neck, followed by the trunk (Table 3) . Upon initial diagnosis of BM, patients tended to have multiple rather than solitary BM (56 vs. 44%), with most of these patients having greater than five BM (Table 3) . Neither the site of primary tumor ( Fig. 1a , P = 0.40) nor its histologic type ( Fig. 2a , P = 0.96 or 1.00 excluding 'other' category) correlated significantly with the initial presence of solitary or multiple BM. BM were more commonly detected in the context of routine screening rather than emergent symptoms (62 vs. 38%); of the patients who presented with symptoms leading to diagnosis of BM, most (76%) were not undergoing routine screening (Table 3) . Although there was no significant correlation between location (in general) and routine screening/symptoms ( Fig. 1b , P = 0.14), patients with BM detected by routine screening were significantly more likely to have tumors originating on the trunk ( Of the 45 patients who were symptomatic, 34 (76%) were not undergoing routine screening and the remaining 11 (24%) were being routinely screening, but had emergent symptoms that led to an unscheduled MRI or CT scan. male and female patients (Fig. 2c , P = 0.56 or 0.74 excluding 'other' category). Finally, although there was no significant correlation in patients who developed BM between location (in general) and their sex (Fig. 1c , P = 0.079), men were more likely to have tumors originating on the trunk (P = 0.092), whereas an extremity was the most common site of primary tumor in women (P = 0.015).
Clinical outcomes in patients with brain metastasis
The median follow-up periods from the date of primary tumor diagnosis and the date of initial BM detection were 3.79 years (range: 0.17-48) and 0.68 years (range: 0.10-13), respectively. As expected, time to first recurrence in BM patients was significantly dependent on their initial tumor stage (P < 0.001; Supplementary Figure 1A , Supplemental digital content 1, http://links. lww.com/MR/A5) as the average recurrence-free survival was shortest for stage III patients (13.8 months), followed by stage II patients (18.6 months) and stage I patients (55.5 months). Similar trends were observed for the average time to first BM (P < 0.001; Supplementary Figure 1B , Supplemental digital content 1, http://links. lww.com/MR/A5) and the average overall survival (P < 0.001; Supplementary Fig. 1C , Supplemental digital content 1, http://links.lww.com/MR/A5). Analysis of primary tumor location indicated that BM patients whose tumors originated on the skin of head and neck had shorter times to first recurrence compared with those with tumors originating on the extremities or the trunk (16.1 vs. 23.8 and 37.3 months, respectively, Fig. 1d ). Similar trends were observed for average time to first BM (Fig. 1e) and average overall survival (Fig. 1f) , although none of these were statistically significant.
The poorer prognosis for patients with primary tumors of the head and neck was driven largely by tumors of the scalp as patients with scalp tumors fared significantly worse than those with other head and neck tumors with respect to time to first recurrence (10.8 vs. 24.8 months, P = 0.007, Fig. 1g ). Times to first BM (28.8 vs. 34 months, Fig. 1h ) and overall survival (24.3 vs. 42.2 months, Fig. 1i ) were also shorter in those with scalp compared with other head and neck melanomas, but these differences were not statistically significant. Patients with NMs had significantly shorter times to first recurrence (11.4 vs. 36.1 months, P = 0.013, Fig. 2d ) and to first BM (25.5 vs. 52.0 months, P = 0.046, Fig. 2e ) than those with superficial spreading tumors. Overall survival was also worse in patients with nodular tumors, but the difference was not statistically significant (P = 0.28, Fig. 2f) . Consistent with the stage-dependent associations with clinical outcomes, times to first recurrence (P < 0.001, Fig. 3a ) and first BM (P = 0.002, Fig. 3b) , and overall survival (P < 0.001, Fig. 3c ) were significantly related to the depth of the primary tumor. Similarly, the presence of ulceration in the primary tumor was associated significantly with shorter time to first recurrence (12.4 vs. 43.2 months, P < 0.001, Fig. 3d ), shorter time to first BM (24.4 vs. 53.6 months, P < 0.001, Fig. 3e) , and worse overall survival (34.6 vs. 68.0. months, P < 0.001, Fig. 3f ).
Finally, we examined whether the initial detection setting of BM (i.e. in context of routine screening vs. presenting symptoms) was associated with different clinical outcomes. We found that BM patients had similar times to first recurrence, first BM, and death irrespective of the detection context (Supplementary Figure 2A 
Discussion
Previous retrospective studies of melanoma patients with BM examined cohorts ranging in size from 49 to 670 patients [5, 6, [8] [9] [10] [11] [12] . The rate of BM in these cohorts was ∼ 10% [5, 6, 8, 9, 11, 13] , which corresponds to the expected risk of developing BM after a diagnosis of primary cutaneous melanoma [2] . Our cohort of 123 melanoma patients with BM represented just over 2% of patients in our melanoma database; this lower percentage likely reflects the composition of our database, which includes many patients with melanoma in situ. Our analysis of melanoma patients with BM and a stage-matched group without BM showed several factors associated significantly with the development of BM that have been described in some, but not all previous studies as discussed below. We observed positive associations of advanced Breslow depth (>4 mm) and an inverse association with the primary tumor location on the leg. We also found that advanced stage, greater tumor depth, nodular type, and ulceration were associated with worse clinical outcomes. Finally, we observed no difference in clinical outcomes between patients whose BM were detected upon routine screening compared with those who presented with neurological symptoms.
Melanoma metastasis from the primary cutaneous tumor often occurs through the lymphatic system, but hematogenous spread is also possible, particularly in cases where there is recurrence following negative sentinel lymph node biopsy or complete lymph node dissection [14] [15] [16] or in early-stage patients who did not receive sentinel node staging and had no evidence of nodal recurrence. Whether BM occurs predominantly through hematogenous or lymphatic spread is not clear, although Jackson et al. [17] reported that for patients with resected stage III melanoma, no lymph node feature (i.e. nodal region, nodal size, number of involved nodes, presence of extracapsular spread) is associated with the development of BM. We did 
not examine these lymph node features or whether patients receive complete lymph node dissection as variables that may be associated with BM. We found that the development of BM was associated with primary tumor location on the scalp and associated inversely with location on the leg. Interestingly, our findings are consistent with a recent report by Gorka et al. [11] showing that the risk of BM correlated with proximity of the primary tumor to the brain. Multiple studies [6, 8, 9, 11, 13, 18, 19] , but not all [10, 17] , have shown that primary tumors of the head and neck were more likely to develop BM. In our cohort, patients with primary tumor of the scalp accounted for most of the differences in clinical outcomes between those with head and neck tumors and other sites, as those with head and neck tumors excluding scalp behaved similarly to those with tumors on an extremity. Similarly, Bottoni et al. [13] reported that axial sites were more likely to develop BM than peripheral ones. Kadakia et al. [18] found that the scalp subsite was associated with worse prognosis among patients with head and neck melanomas. We have reported previously that blood and lymphatic vessel density is increased in the scalp compared with the torso and extremity, as indicated by CD31 and D2-40 staining, respectively [20] . Although correlations between lymphatic density and melanoma metastasis have been reported [21] , the issue remains controversial [22] and a histological study of scalp melanomas found high rates of both vascular and lymphatic invasion [23] . In addition, Hung et al. [24] observed angiotropism in 14/20 primary tumors that developed BM. We could not address this issue as the presence or absence of lymphovascular invasion was not recorded in our database.
Our study confirms the correlation of BM development with advanced tumor stage, particularly including Breslow depth more than 4 mm [5, 6, 8, 11, 19] as reported by others. We did not find that ulceration was associated with BM, as reported in two previous studies [10, 17] , although multiple other studies [5, 6, 8, 9, 11] reported a correlation. Curiously, Frankel et al. [10] found that thinner primary tumors were associated with BM, although we observed a lower frequency of BM in patients with tumors less than 1 mm in depth. Although other studies [8, 25] found that NM histologic type was associated with the development of BM, we did not observe this when corrected for tumor depth. Our patients with BM were predominantly men, as found in other studies [8, 12, 17, 26] , although our stage-matched control group was similarly male-predominant. A review of multiple studies concluded that male patients with BM have a poorer prognosis [18] , although we did not address that issue here. We observed a similar distribution of superficial spreading melanoma and NM histologic types in our male and female patients with BM, although female patients had relatively fewer primary tumors on the scalp. All the clinical outcomes that we examined were stage dependent as patients with stage III tumors (followed by stage II and stage I tumors) had shorter times to first recurrence, first BM, and death. These findings are consistent with those of Bottoni et al. [13,] who reported that sentinel lymph node positivity was the strongest predictor for the development of BM.
Several studies noted that the mutational genotype of the primary tumor was associated with the development of BM. Jakob et al. [27] reported a higher prevalence in BRAF-mutant (24%) and NRAS-mutant (23%) patients than in 'wild-type' patients (12%) and Maxwell et al. [28] similarly found that BRAF mutations were associated with an increased risk of BM. However, Schoenewolf et al. [25] found that BRAF-mutant versus wild-type tumors showed no significant differences in propensity for BM. In our cohort, we did not find a difference in BRAF-positivity in patients with BM, although most patients in our control group did not undergo mutation testing.
Our study had several limitations inherent in a retrospective analysis including potential patient selection bias and incomplete data for some variables of potential importance. In addition, most of our patients were diagnosed with and succumbed to BM before the advent of newer systemic therapies as noted above, and we did not examine the effect of the surgical, radiotherapeutic, or medical treatments that they received. The ideal control group would be patients who developed metastatic disease at sites other than the brain. A limitation of our control group is that although these patients were matched to our BM patients by initial tumor stage, not all these patients ultimately developed metastatic disease. In fact, we could confirm the development of stage IV disease in only 10/237 (8.4%) of our controls and lack of distant metastasis in only 79/237 (33.3%); for the rest of our controls (100/237, 42.2%), we did not have recent follow-up to ascertain this information. In reviewing the literature, we note that of nine studies examining melanoma BM, four had no control group [4, 12, 26, 29] , four had a control group similar to as ours [5, 6, 8, 9] , and only one had a control group with nonbrain distant metastasis [10] .
Approximately 12% of patients with metastatic melanoma will have asymptomatic BM [30] . Vecchio et al. [7] found that such patients without clinical symptoms experienced a statistically significant better survival than patients with clinical symptoms, although this issue was not addressed in most previous studies of melanoma BM. By contrast, we found no differences in the clinical outcomes (times to first recurrence, first BM, and death) in patients where BM was first detected by routine screening compared with those who had clinical symptoms prompting an imaging study that indicated BM. Although the presence of symptoms may reflect the presence of more severe brain involvement, it may also result in earlier detection and treatment. However, detection of BM on screening may lead to the appearance of improved survival because of lead time and length time biases. Thus, the similar survival irrespective of the method of BM detection may indicate that survival is driven primarily by how treatable the systemic disease burden is. Although the implications for screening guidelines are unclear, it is important to note that whereas many of our patients who developed BM before 2010 may not have benefitted considerably from earlier detection of BM, this may not be the case in the present era with the advent of targeted and immunotherapies.
